FDA's NDA And BLA Approvals: Fiasp, Ascor
Original new drugs and biologics approved by US FDA.
You may also be interested in...
With only slight potential advantages in some types of patients, ultra-rapid insulins will likely still need to compete on price to be more widely successful, analysts say.
Novo Nordisk is gearing towards the potential launch of its ultra fast-acting insulin aspart, Fiasp, in India. Pricing and how the product will be positioned alongside NovoRapid (conventional insulin aspart) are expected to be closely watched by competition.
Sanofi will pay $175m up front for rights to commercialize J&J’s potential first-in-class vaccine against E. coli. The two companies will share profits.